| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ... Cancer discovery 3 (12), 1355-1363, 2013 | 1349 | 2013 |
| Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor CL Christensen, N Kwiatkowski, BJ Abraham, J Carretero, F Al-Shahrour, ... Cancer cell 26 (6), 909-922, 2014 | 472 | 2014 |
| Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression C Xu, CM Fillmore, S Koyama, H Wu, Y Zhao, Z Chen, GS Herter-Sprie, ... Cancer cell 25 (5), 590-604, 2014 | 391 | 2014 |
| Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit Z Zhu, AR Aref, TJ Cohoon, TU Barbie, Y Imamura, S Yang, SE Moody, ... Cancer discovery 4 (4), 452-465, 2014 | 209 | 2014 |
| Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer H Zhang, J Qi, JM Reyes, L Li, PK Rao, F Li, CY Lin, JA Perry, MA Lawlor, ... Cancer discovery 6 (9), 1006-1021, 2016 | 124 | 2016 |
| Autophagy inhibition dysregulates TBK1 signaling and promotes pancreatic inflammation S Yang, Y Imamura, RW Jenkins, I Cañadas, S Kitajima, A Aref, ... Cancer immunology research 4 (6), 520-530, 2016 | 106 | 2016 |
| Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome … Z Chen, E Akbay, O Mikse, T Tupper, K Cheng, Y Wang, X Tan, A Altabef, ... Clinical Cancer Research 20 (5), 1204-1211, 2014 | 70 | 2014 |
| Cardiovascular disease and cancer: shared risk factors and mechanisms NS Wilcox, U Amit, JB Reibel, E Berlin, K Howell, B Ky Nature Reviews Cardiology, 1-15, 2024 | 57 | 2024 |
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013; 3 (12): 1355–1363. doi: 10.1158/2159-8290 EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ... CD-13-0310.[Europe PMC free article][Abstract][CrossRef][Academic Search], 0 | 53 | |
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013; 3 (12): 1355–63. doi: 10.1158/2159-8290 EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ... CD-13-0310, 0 | 24 | |
| Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non–squamous Non–small Cell Lung Cancer After Progression on Platinum and Pemetrexed CA Ciunci, JB Reibel, TL Evans, R Mick, JM Bauml, C Aggarwal, ... Clinical Lung Cancer 23 (4), e310-e316, 2022 | 3 | 2022 |
| Social determinants of health mediate racial disparities in cardiovascular disease in men with prostate cancer BG Demissei, K Ko, A Huang, DJ Lee, AG Doucette, AM Smith, NS Wilcox, ... Cardio Oncology 6 (3), 390-401, 2024 | 2 | 2024 |
| Erratum to Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor [Cancer Cell 26,(2014) 909-922] CL Christensen, N Kwiatkowski, BJ Abraham, J Carretero, F Al-Shahrour, ... Cancer Cell 27 (1), 149, 2015 | 2 | 2015 |
| Real-World Impact of the Platinum Chemotherapy Shortage on US Patients with Advanced Cancer JB Reibel, LL Sun, RB Parikh, N Mahmud, LP Martin, RA Hubbard, ... JNCI: Journal of the National Cancer Institute, djae307, 2024 | | 2024 |
| 1548P Real-world impact of the platinum chemotherapy shortage on advanced cancer patients JB Reibel, R Hubbard, L Sun, RB Parikh, LP Martin, R Mamtani Annals of Oncology 35, S942-S943, 2024 | | 2024 |
